Literature DB >> 33975918

Efficacy of perineural versus intravenous dexmedetomidine as a peripheral nerve block adjunct: a systematic review.

Nasir Hussain1, Chad M Brummett2, Richard Brull3, Yousef Alghothani1, Kenneth Moran1, Tamara Sawyer4, Faraj W Abdallah5.   

Abstract

BACKGROUND: Dexmedetomidine is an effective local anesthetic adjunct for peripheral nerve blocks. The intravenous route for administering dexmedetomidine has been suggested to be equally effective to the perineural route; but comparative evidence is conflicting.
OBJECTIVES: This evidence-based review evaluated trials comparing the effects of intravenous to perineural dexmedetomidine on peripheral nerve block characteristics in adult surgical patients. Our primary aim was to evaluate the durations of sensory and motor blockade. Duration of analgesia, onset times of sensory and motor blockade, analgesic consumption, rest pain, and dexmedetomidine-related adverse events were evaluated as secondary outcomes. EVIDENCE REVIEW: We sought randomized trials comparing the effects of intravenous to perineural dexmedetomidine on peripheral nerve block characteristics. The Cochrane Risk of Bias tool and the Grades of Recommendation, Assessment, Development, and Evaluation criteria was used to evaluate the quality of evidence for when an outcome was reported by at least three studies.
RESULTS: Ten studies compared intravenous and perineural dexmedetomidine in the setting of upper extremity blocks (seven), lower extremity blocks (two), and truncal block (one). The doses of dexmedetomidine supplementing long-acting local anesthetics varied between a predetermined dose (50 μg) and a weight-based dose (0.5 μg/kg-1.0 μg/kg). Clinical diversity precluded quantitative pooling; and evidence is presented as a systematic review. Compared with the intravenous route, moderate quality evidence found that perineural dexmedetomidine prolonged the duration of sensory blockade in four of six trials and motor blockade in five of seven trials. Perineural dexmedetomidine also hastened the onset of sensory and motor blockade in three of six trials. No differences were reported for the remaining outcomes; and intravenous dexmedetomidine was not superior for any outcome in any of the trials.
CONCLUSIONS: Moderate quality evidence appears to suggest that intravenous dexmedetomidine is an inferior peripheral nerve block adjunct compared with perineural dexmedetomidine. Perineural dexmedetomidine is associated with longer durations and faster onset of sensory and motor blockade. © American Society of Regional Anesthesia & Pain Medicine 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  anesthesia; local; nerve block; pain; postoperative

Mesh:

Substances:

Year:  2021        PMID: 33975918     DOI: 10.1136/rapm-2020-102353

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  4 in total

1.  Dexmedetomidine prolongs the duration of local anesthetics when used as an adjuvant through both perineural and systemic mechanisms: a prospective randomized double-blinded trial.

Authors:  Quanguang Wang; Riyong Zhou; Nana Bao; Kejian Shi; YiQuan Wu; Yuting He; Zhengjie Chen; Yuan Gao; Yun Xia; Thomas J Papadimos
Journal:  BMC Anesthesiol       Date:  2022-06-07       Impact factor: 2.376

2.  Efficacy of dexmedetomidine as an adjuvant in femoral nerve block for post-op pain relief in hip surgery: A prospective randomized double-blind controlled study.

Authors:  Chetna P Goel; Sameer Desai
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2021-10-12

3.  The Use of Multimodal Perineural Adjuvants in Pediatric Peripheral Nerve Blocks: Technique and Experiences.

Authors:  Sampaguita P Tafoya; Sundeep S Tumber
Journal:  Cureus       Date:  2022-03-15

4.  Low-dose dexmedetomidine as a perineural adjuvant for postoperative analgesia: a randomized controlled trial.

Authors:  Wei Liu; Jingwen Guo; Jun Zheng; Bin Zheng; Xiangcai Ruan
Journal:  BMC Anesthesiol       Date:  2022-08-05       Impact factor: 2.376

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.